SOLVD Health Announces FDA Approval to Expand AvertD® Sample Collection to Include Blood, Enabling Broad Availability of the First and Only FDA‐Approved Genetic Test Indicated to Assess Genetic Risk of OUD Prior to First Oral Opioid Prescription

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a privately held company focused on preventing disease through actionable and personalized health information, today announced broad availability of AvertD® following FDA approval to expand sample collection to include venous whole blood. AvertD is the first and only FDA‐approved genetic test indicated to assess genetic risk of opioid use disorder (OUD) prior to first exposure to oral opioids for acute pain. AvertD is a qualitative genotyping test that